About this trial

Pancreatic radiofrequency ablation (RFA) could therefore be an alternative to the monitoring of pancreatic neuroendocrine tumors (PNETs) and more particularly nonfunctioning PNETs (NF-PNETs), which is costly and anxiety-inducing for patients. To date, only a few small studies have evaluated this treatment and the results are encouraging. It appears necessary to consider a large-scale study to ensure the efficacy and low morbidity of pancreatic RFA applied to PNETs.

Eligibility criteria

Qualifiers

Pancreatic mass of less than 2cm on MRI, or CT scan if contraindicated by MRI;

Diagnosis of neuroendocrine tumor on biopsy under high echo-endoscopy (HEE) with Ki67<3%,

Non-secretory lesion.

Homogeneous HEE contrast taking;

Disqualifiers

Pregnant or likely to become pregnant (without effective contraception) or breastfeeding ;

A person in an emergency situation or deprived of liberty or placed under the authority of a tutor.

Life expectancy < 1 year;

Severe hemostasis disorders;

Trial design

Treatments tested in this trial

  • Radiofrequency ablation

Treatment groups

82 Participants
are divided into 1 treatment group

Locations

1
Institut Paoli Calmettes13009, Marseille France

Sponsors and collaborators

Institut Paoli-Calmettes

Lead sponsor